Welcome to our dedicated page for Imax SEC filings (Ticker: IMAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From record-breaking box-office weekends to multi-year theater signings in China, IMAX Corporation’s financial pulse beats inside its SEC disclosures. Each 10-K details giant-screen installs, backlog totals, and revenue splits with exhibitors, while every 10-Q revisits film remastering margins and technology licensing momentum. Yet these insights hide in hundreds of pages of technical language.
Stock Titan’s AI translates those dense documents the instant they appear on EDGAR. Want IMAX insider trading Form 4 transactions? Real-time alerts surface each executive trade. Need the most recent IMAX quarterly earnings report 10-Q filing? Our summaries highlight per-screen averages and joint-venture revenue in plain English. Coverage spans every critical form:
- 10-K annual report – network size, backlog, risk factors simplified
- 10-Q quarterly earnings with AI commentary and trend visuals
- 8-K material events – new studio partnerships and technology launches explained
- Proxy statement – IMAX proxy statement executive compensation decoded
- Form 4 – IMAX Form 4 insider transactions real-time
Professionals use these outputs to monitor screen-count expansion, evaluate royalty streams, and track incentive alignment through IMAX executive stock transactions Form 4. If you ask, “understanding IMAX SEC documents with AI” or search for “IMAX earnings report filing analysis,” this page delivers. Our AI keeps every IMAX annual report 10-K simplified and IMAX 8-K material events explained at your fingertips, saving hours and sharpening decisions.
Seller Mark Welton has filed a notice of proposed sale of 25000 Class A common shares of IMAX on the NYSE through Merrill Lynch, with an aggregate market value of 982000. The issuer had 53798934 Class A common shares outstanding.
The securities to be sold were acquired on 03/07/2025 via vesting of 18234 RSUs and 6766 PSUs recorded as compensation, with payment dated 03/07/2025. During the past three months, Welton has already sold 49504 Class A common shares, generating gross proceeds of 1743926.91.
IMAX Corp officer Mark Welton, President IMAX Global Theatres, reported a sale of 25,000 common shares on 12/15/2025 at $39.28 per share. The sale was made pursuant to a Rule 10b5-1 Plan dated September 15, 2025.
After this transaction, he beneficially owns 128,323 common shares, and his remaining restricted share unit balance is 70,609.
IMAX Corporation executive Robert D. Lister, the Chief Legal Officer and Senior Executive Vice President, reported a charitable transfer of company stock. On December 11, 2025, he gifted 2,000 common shares of IMAX Corporation to a donor-advised fund, with the shares to be used for charitable purposes. The Form 4 shows the transaction at a price of $0.00, reflecting that this was a gift rather than a sale.
Following this transaction, Mr. Lister beneficially owns 159,421 common shares and holds 70,609 restricted share units. The filing notes that the timing of the gift relates to changes in tax regulations affecting charitable donations that take effect on January 1, 2026.
An affiliate of IMAX has filed a Form 144 notice covering the planned sale of 2,652 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an indicated aggregate market value of $95,864.23. The filing notes that these common shares were acquired on 11/24/2025 by exercising stock options under a registered plan, with payment made in cash on the same date. The notice also reports that 53,798,934 common shares were outstanding at the time referenced.
IMAX Corporation’s Chief Financial Officer and EVP, Natasha Fernandes, reported an options exercise and share sale involving the company’s common shares. On 11/24/2025, she exercised 2,652 stock options with an exercise price of $22.49 per share, converting them into 2,652 common shares. That same day, she sold 2,652 common shares at an average price of $36.1479 per share, returning her directly held common share balance to 31,257 shares.
The options were originally granted in 2019 and are scheduled to expire on March 7, 2026, having vested in four annual installments between 2020 and 2023. Following these transactions, Ms. Fernandes’ aggregate remaining outstanding restricted share unit balance is 39,734, and her common share balance remains 31,257, reflecting a same-day exercise-and-sale transaction structure.
IMAX Corp: Orbis Investment Management Limited and Allan Gray Australia Pty Ltd filed Amendment No. 4 to Schedule 13G, reporting beneficial ownership in IMAX common stock. They report 5,241,883 shares, representing 9.7% of the class, with the event dated September 30, 2025.
Orbis has sole voting and dispositive power over 5,222,063 shares, and Allan Gray Australia has sole voting and dispositive power over 19,820 shares. The filers certify the holdings were acquired and are held in the ordinary course of business and not to change or influence control. They are classified as non‑U.S. institutions equivalent to investment advisers.
IMAX: Macquarie entities filed Amendment No. 2 to Schedule 13G reporting beneficial ownership of 4,612,983 common shares, representing 8.58% of the class as of 09/30/2025.
Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust each report sole voting and sole dispositive power over 4,612,983 shares. Macquarie Group Limited reports an aggregate beneficial amount of 4,612,983 shares with zero sole or shared voting/dispositive power on its cover page.
The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
IMAX Corp reported a Form 4 for CEO and Director Richard L. Gelfond, who gifted 40,000 common shares on 11/10/2025 (transaction code G) to a donor‑advised fund for charitable purposes. After the transfer, he beneficially owns 564,599 common shares directly.
The filing also lists his outstanding awards following the transaction: 1,818,695 options and 294,433 restricted share units. It states the timing relates to changes in tax regulations taking effect on 01/01/2026.
IMAX (IMAX) executive Mark Welton reported an option exercise and share sale. On 11/10/2025, he exercised stock options into 49,504 common shares at $22.49 per share and sold 49,504 common shares at a price of $35.228.
Following these transactions, he beneficially owns 153,323 common shares directly. The filing notes 70,609 restricted share units outstanding after these transactions and that the options exercised were issued in 2019 and set to expire on March 7, 2026.
IMAX Chief Commercial Officer Giovanni M. Dolci reported an option exercise and same‑day sale. On 11/10/2025, he exercised 6,188 stock options at $22.49 and sold 6,188 common shares at a weighted average price of $34.2452, leaving 33,000 common shares held directly.
The options were issued in 2019 and are set to expire on March 7, 2026. The filing notes remaining restricted share units of 21,574 following these transactions.
FAQ
What is the current stock price of Imax (IMAX)?
What is the market cap of Imax (IMAX)?
